212 related articles for article (PubMed ID: 22923147)
21. Lesson of the month 2: Autoimmune sequelae of anti-GAD antibodies - thinking outside the box.
Ward RJ; Varughese GI; Jose B; Abraham RJ
Clin Med (Lond); 2017 Oct; 17(5):473-474. PubMed ID: 28974603
[TBL] [Abstract][Full Text] [Related]
22. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
23. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
24. [Autoantibodies associated with autoimmune-mediated cerebellar ataxia].
Mitoma H; Nanri K
Brain Nerve; 2013 Apr; 65(4):355-64. PubMed ID: 23568983
[TBL] [Abstract][Full Text] [Related]
25. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy.
Pedroso JL; Braga-Neto P; Dutra LA; Barsottini OG
Arq Neuropsiquiatr; 2011 Dec; 69(6):993. PubMed ID: 22297896
[No Abstract] [Full Text] [Related]
26. Experience with immunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Rouco I; Hurtado P; Castaño L; Zarranz JJ
Neurologia; 2015 May; 30(4):247-9. PubMed ID: 24075582
[No Abstract] [Full Text] [Related]
27. Rapidly progressing cerebellar ataxia associated with anti-GAD antibodies.
Quintas S; Ruiz RL; Zapata-Wainberg G; Vivancos J
Neurologia (Engl Ed); 2018 May; 33(4):273-275. PubMed ID: 27091680
[No Abstract] [Full Text] [Related]
28. Efficacy of oral corticosteroids therapy in anti-glutamic acid decarboxylase antibodies cerebellar ataxia.
di Biase L; Assenza G; Iorio R; Melgari JM; Salomone G; Marano M; Muda AO; Di Lazzaro V
Parkinsonism Relat Disord; 2016 Sep; 30():78-80. PubMed ID: 27236207
[No Abstract] [Full Text] [Related]
29. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
30. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
31. [A case of anti-gliadin-antibody-positive cerebellar ataxia effectively treated with intravenous immunoglobulin in which voxel-based morphometry and FineSRT were diagnostically useful].
Nanri K; Otsuka T; Takeguchi M; Taguchi T; Ishiko T; Mitoma H; Koizumi K
Rinsho Shinkeigaku; 2009 Jan; 49(1):37-42. PubMed ID: 19227895
[TBL] [Abstract][Full Text] [Related]
32. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
[TBL] [Abstract][Full Text] [Related]
33. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
[TBL] [Abstract][Full Text] [Related]
34. Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.
Flores-Cantu H; Camara-Lemarroy CR; Calderon-Hernandez HJ; Zapata-Rivera MA; Villareal-Perez JZ; Villareal-Velazquez HJ
Cerebellum; 2015 Jun; 14(3):375-7. PubMed ID: 25575726
[No Abstract] [Full Text] [Related]
35. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
Iwasaki H; Sato R; Shichiri M; Hirata Y
Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
[TBL] [Abstract][Full Text] [Related]
36. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Rakocevic G; Raju R; Dalakas MC
Arch Neurol; 2004 Jun; 61(6):902-4. PubMed ID: 15210528
[TBL] [Abstract][Full Text] [Related]
37. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Vulliemoz S; Vanini G; Truffert A; Chizzolini C; Seeck M
J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):187-9. PubMed ID: 17229747
[TBL] [Abstract][Full Text] [Related]
38. Anti-glutamic acid decarboxylase antibody positive neurological syndromes.
Tohid H
Neurosciences (Riyadh); 2016 Jul; 21(3):215-22. PubMed ID: 27356651
[TBL] [Abstract][Full Text] [Related]
39. The clinical relevance of anti-glutamic acid decarboxylase antibodies in children with encephalitis/encephalopathy.
Hou JY; Liu HU; Kuo CY; Liu YH; Lin JJ; Hsieh MY; Hung PC; Cheng YT; Su IC; Wang HS; Chou IJ; Lin KL
Front Neurosci; 2022; 16():1081580. PubMed ID: 36817097
[TBL] [Abstract][Full Text] [Related]
40. Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
Guasp M; Solà-Valls N; Martínez-Hernández E; Gil MP; González C; Brieva L; Saiz A; Dalmau J; Graus F; Ariño H
J Neuroimmunol; 2016 Nov; 300():15-17. PubMed ID: 27806870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
